EUVIMEDEUVIMED entdecken
EditorialKommentar

RIPK2 inhibition gets the NOD for asthma

Henry J McSorley

European Respiratory Journal · 2024

DOI: 10.1183/13993003.01372-2024 ↗

Kurz gefasst

Editorial in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Henry J McSorley. Beteiligte Einrichtung: School of Life Sciences, University of Dundee, Dundee, UK hmcsorley001@dundee.ac.uk. Hauptthemen laut MEDLINE: Asthma, Receptor-Interacting Protein Serine-Threonine Kinase 2. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaReceptor-Interacting Protein Serine-Threonine Kinase 2HumansAnimalsMiceNod2 Signaling Adaptor Protein

Substanzen

Receptor-Interacting Protein Serine-Threonine Kinase 2Nod2 Signaling Adaptor Protein

Autor:innen und Institutionen

  • School of Life Sciences, University of Dundee, Dundee, UK hmcsorley001@dundee.ac.uk.

Zitieren

APA

McSorley, H. J. (2024). RIPK2 inhibition gets the NOD for asthma. European Respiratory Journal. https://doi.org/10.1183/13993003.01372-2024

Vancouver

McSorley HJ. RIPK2 inhibition gets the NOD for asthma. European Respiratory Journal. 2024. doi:10.1183/13993003.01372-2024

BibTeX
@article{McSorley2024,
  author = {McSorley, Henry J},
  title = {RIPK2 inhibition gets the NOD for asthma},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.01372-2024}
}
Kostenlos starten →